Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide

Jeremy D. Gates; Guy T. Clifton; Linda C. Benavides; Alan K. Sears; Mark G. Carmichael; Matthew T. Hueman; Jarrod P. Holmes; Yusuf H. Jama; Mohamed Mursal; Athina Zacharia; Kathy Ciano; Steven Khoo; Alexander Stojadinovic; Sathibalan Ponniah; George E. Peoples

doi:10.1016/j.vaccine.2010.09.029

Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide

Jeremy D. Gates, Guy T. Clifton, Linda C. Benavides, Alan K. Sears, Mark G. Carmichael, Matthew T. Hueman, Jarrod P. Holmes, Yusuf H. Jama, Mohamed Mursal, Athina Zacharia, Kathy Ciano, Steven Khoo, Alexander Stojadinovic, Sathibalan Ponniah, George E. Peoples^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Regulatory T cells (T_Reg), CD4⁺CD25⁺FOXP3⁺, are implicated in suppressing tumor immune responses. We analyzed peripheral blood lymphocytes (PBL) from breast cancer patients receiving a modified HLA class II HER2/neu peptide (AE37) vaccine for T_Reg cells and correlated their levels with vaccine-specific immune responses. The mean CD4⁺CD25⁺FOXP3⁺ T_Reg cells decreased in patients with vaccination with no significant difference in serum TGF-β levels. IFN-γ ELISPOT and DTH increased after vaccination with a good correlation between T_Reg cell reduction and size of DTH to AE37. The T_Reg cell reduction and associated immune response suggest that AE37 may be clinically useful.

Original language	English
Pages (from-to)	7476-7482
Number of pages	7
Journal	Vaccine
Volume	28
Issue number	47
DOIs	https://doi.org/10.1016/j.vaccine.2010.09.029
State	Published - 3 Nov 2010
Externally published	Yes

Keywords

HER2/neu
Regulatory T cell
Vaccine

Access to Document

10.1016/j.vaccine.2010.09.029

Cite this

Gates, J. D., Clifton, G. T., Benavides, L. C., Sears, A. K., Carmichael, M. G., Hueman, M. T., Holmes, J. P., Jama, Y. H., Mursal, M., Zacharia, A., Ciano, K., Khoo, S., Stojadinovic, A., Ponniah, S., & Peoples, G. E. (2010). Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide. Vaccine, 28(47), 7476-7482. https://doi.org/10.1016/j.vaccine.2010.09.029

@article{47ada6e422fd4fd9881dd59c6957a0d1,

title = "Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide",

abstract = "Regulatory T cells (TReg), CD4+CD25+FOXP3+, are implicated in suppressing tumor immune responses. We analyzed peripheral blood lymphocytes (PBL) from breast cancer patients receiving a modified HLA class II HER2/neu peptide (AE37) vaccine for TReg cells and correlated their levels with vaccine-specific immune responses. The mean CD4+CD25+FOXP3+ TReg cells decreased in patients with vaccination with no significant difference in serum TGF-β levels. IFN-γ ELISPOT and DTH increased after vaccination with a good correlation between TReg cell reduction and size of DTH to AE37. The TReg cell reduction and associated immune response suggest that AE37 may be clinically useful.",

keywords = "HER2/neu, Regulatory T cell, Vaccine",

author = "Gates, {Jeremy D.} and Clifton, {Guy T.} and Benavides, {Linda C.} and Sears, {Alan K.} and Carmichael, {Mark G.} and Hueman, {Matthew T.} and Holmes, {Jarrod P.} and Jama, {Yusuf H.} and Mohamed Mursal and Athina Zacharia and Kathy Ciano and Steven Khoo and Alexander Stojadinovic and Sathibalan Ponniah and Peoples, {George E.}",

note = "Funding Information: Supported by the United States Military Cancer Institute, Department of Surgery, Uniformed Services University of the Health Sciences, and the Department of Clinical Investigation at Walter Reed Army Medical Center. The clinical trial was funded by Antigen Express. ",

year = "2010",

month = nov,

day = "3",

doi = "10.1016/j.vaccine.2010.09.029",

language = "English",

volume = "28",

pages = "7476--7482",

journal = "Vaccine",

issn = "0264-410X",

number = "47",

}

Gates, JD, Clifton, GT, Benavides, LC, Sears, AK, Carmichael, MG, Hueman, MT, Holmes, JP, Jama, YH, Mursal, M, Zacharia, A, Ciano, K, Khoo, S, Stojadinovic, A, Ponniah, S & Peoples, GE 2010, 'Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide', Vaccine, vol. 28, no. 47, pp. 7476-7482. https://doi.org/10.1016/j.vaccine.2010.09.029

TY - JOUR

T1 - Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide

AU - Gates, Jeremy D.

AU - Clifton, Guy T.

AU - Benavides, Linda C.

AU - Sears, Alan K.

AU - Carmichael, Mark G.

AU - Hueman, Matthew T.

AU - Holmes, Jarrod P.

AU - Jama, Yusuf H.

AU - Mursal, Mohamed

AU - Zacharia, Athina

AU - Ciano, Kathy

AU - Khoo, Steven

AU - Stojadinovic, Alexander

AU - Ponniah, Sathibalan

AU - Peoples, George E.

N1 - Funding Information: Supported by the United States Military Cancer Institute, Department of Surgery, Uniformed Services University of the Health Sciences, and the Department of Clinical Investigation at Walter Reed Army Medical Center. The clinical trial was funded by Antigen Express.

PY - 2010/11/3

Y1 - 2010/11/3

N2 - Regulatory T cells (TReg), CD4+CD25+FOXP3+, are implicated in suppressing tumor immune responses. We analyzed peripheral blood lymphocytes (PBL) from breast cancer patients receiving a modified HLA class II HER2/neu peptide (AE37) vaccine for TReg cells and correlated their levels with vaccine-specific immune responses. The mean CD4+CD25+FOXP3+ TReg cells decreased in patients with vaccination with no significant difference in serum TGF-β levels. IFN-γ ELISPOT and DTH increased after vaccination with a good correlation between TReg cell reduction and size of DTH to AE37. The TReg cell reduction and associated immune response suggest that AE37 may be clinically useful.

AB - Regulatory T cells (TReg), CD4+CD25+FOXP3+, are implicated in suppressing tumor immune responses. We analyzed peripheral blood lymphocytes (PBL) from breast cancer patients receiving a modified HLA class II HER2/neu peptide (AE37) vaccine for TReg cells and correlated their levels with vaccine-specific immune responses. The mean CD4+CD25+FOXP3+ TReg cells decreased in patients with vaccination with no significant difference in serum TGF-β levels. IFN-γ ELISPOT and DTH increased after vaccination with a good correlation between TReg cell reduction and size of DTH to AE37. The TReg cell reduction and associated immune response suggest that AE37 may be clinically useful.

KW - HER2/neu

KW - Regulatory T cell

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=77958196145&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.09.029

DO - 10.1016/j.vaccine.2010.09.029

M3 - Article

C2 - 20858449

AN - SCOPUS:77958196145

SN - 0264-410X

VL - 28

SP - 7476

EP - 7482

JO - Vaccine

JF - Vaccine

IS - 47

ER -

Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide

Abstract

Keywords

Access to Document

Fingerprint

Cite this